10-7
U.S. Treasury yields hit 24-year highs as 10-year reaches 5.35% and 30-year climbs to 5.73%
Long-term U.S. Treasury yields climbed to 24-year highs on Wednesday, with the 10-year and 30-year yields touching 5.35% and 5.73%, the highest levels since 2002. European stocks slid, with the Stoxx 600 down 1% and major indexes in France, Germany and Italy posting steep losses. U.S. equities also opened lower, with the S&P 500 off 0.6% and the Nasdaq Composite down 0.8%, while Brent crude rose 1% to above $102 a barrel. The U.S. Treasury Department was set to sell a $39 billion 10-year note tranche later that day.
10-7
10-7
Consumers sue Starbucks over “sugarfree” protein drinks alleged to contain 13–21 grams of sugar per serving
U.S. consumers have filed a federal lawsuit against Starbucks, alleging its “sugarfree” protein drinks contain 13 to 21 grams of sugar per serving—an amount the suit compares to a Kit Kat bar. The plaintiffs argue the “sugarfree” label would mislead a reasonable consumer. The case seeks damages for consumers nationwide, and asks the court to order Starbucks to stop using the “sugarfree” label on products that contain sugar. Starbucks has not publicly responded.
10-7
10-1
California judge clears Paramount Skydance to close $110 billion Warner Bros. Discovery takeover
A California judge formally approved Paramount Skydance’s settlement with California and other states, removing the last hurdle to closing its $110 billion takeover of Warner Bros. Discovery. The merger would combine assets including CBS News and CNN, HBO Max and Paramount+, and the Warner Bros. and Paramount Pictures studios. Paramount Skydance CEO David Ellison named Mattel CEO Ynon Kreiz as co-CEO of the combined company and pledged to invest more than $1 billion in U.S. film production and worker training. Paramount shares have fallen more than 20% since the start of the year as the deal remained in limbo.
10-1
9-30
Lilly’s retatrutide trial shows Type 2 diabetes patients lost up to 60 pounds over 80 weeks
Eli Lilly’s GLP-1 drug retatrutide posted late-stage results in The Lancet and the New England Journal of Medicine. The data showed people with Type 2 diabetes lost up to 60 pounds (about 23%), while obese patients without diabetes lost up to 70 pounds (about 25%). The trials also found up to 40% of patients reached an A1C below 5.7%, under the threshold used to diagnose diabetes and prediabetes.
9-30